Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article reviews the pathophysiology, diagnosis, and treatment of androgenic alopecia but reports no new clinical findings.

In this study, the authors highlighted treatments for androgenetic alopecia, noting that combination therapies with drugs like minoxidil and antiandrogens often require at least 6 months for clinical improvement, while also emphasizing the value of patient counseling for informed treatment choices.

This study reports that dermatologists account for only 23% of social media posts about AGA therapy but have the highest average follower count, suggesting they could significantly enhance education on these platforms.

This article reviews the possible therapeutic activities of Angelica gigas Nakai root extracts and their components, noting their potential effects on neuro-cognitive, metabolic, and other health conditions, and reports no new clinical results.

This article reviews the classification systems for androgenetic alopecia and reports no new research findings.

This study analyzed pediatric and adult patients with antibody deficiencies at a PID center, finding frequent severe infections and genetic mutations, with treatment primarily involving IVIG replacement therapy.

This review discusses recent research on the use of concentrated growth factor (CGF) for treating androgenetic alopecia, highlighting its potential to enhance hair regrowth and improve hair density but noting the need for high-quality clinical trials.

This abstract introduces a historical perspective on Dorothy Osborn's research about the hereditary nature of common baldness but reports no new study results.

In this study, low-dose oral minoxidil was found to be an effective and safe treatment for androgenetic alopecia, showing comparable outcomes in patients with AGA alone and those with AGA unmasked by telogen effluvium.

This article reviews androgenetic alopecia and its genetic and hormonal influences, treatment options like minoxidil and finasteride, and its potential associations with other health conditions, reporting no new clinical results.

This comprehensive review analyzes androgenetic alopecia treatments, discussing the mechanisms, costs, efficacy, and safety of FDA-approved drugs like minoxidil and finasteride, as well as newer non-FDA-approved options that have shown effectiveness across various studies.

In this review, the authors explored current and novel treatment options for androgenetic alopecia, noting both FDA-approved pharmacologic treatments like Minoxidil and Finasteride and various non-pharmacologic and surgical methods, including hair transplantation and scalp micro-pigmentation.

This study found that non-ablative Er:YAG laser treatment, alone or combined with other therapies, effectively improved hair quality and reduced AGA grade in patients, with high satisfaction reported and no adverse reactions.

This article presents a case study of a 16-year-old male with GAPO syndrome, characterized by growth retardation, alopecia, pseudoanodontia, and optic atrophy, who sought dental treatment for missing teeth.

This study found that young adult men with moderate to severe AGA have poorer semen quality compared to those with normal to mild AGA.

This chapter provides a comprehensive review of androgenetic alopecia, covering its key physiological mechanisms, diagnostic methods, and a variety of treatment options ranging from topical therapies to aesthetic and regenerative procedures, emphasizing recent advances observed in dermatological practice.

This study found that ACOD1 deficiency in dermal papilla cells promotes mitochondrial dysfunction and contributes to cellular senescence in androgenetic alopecia, suggesting ACOD1 as a potential therapeutic target and 4-octyl itaconate as a promising treatment option for AGA.

This article reviews the causes, clinical features, and treatment options for androgenetic alopecia, but provides no new clinical findings.

This article outlines management guidelines for androgenetic alopecia, highlighting that continued treatment with medications like finasteride or minoxidil typically halts progression and improves hair condition in most mild to moderate cases.

This review discusses therapeutic options for androgenetic alopecia, noting that while antiandrogen treatments prevent further hair loss and promote some regrowth, dramatic results are rare.

This study reports that Korean adolescents with androgenetic alopecia tend to have milder symptoms than adults and a higher prevalence of family history of alopecia.

This study describes a multifunctional hydrogel system designed to treat androgenetic alopecia by integrating nanozymes for reactive oxygen species clearance and melanin nano photothermal agents to enhance hair follicle health, suggesting potential for multi-target precision therapy and improved hair growth.

In this study, women with androgenetic alopecia showed higher cholesterol levels and carotid artery thickness, suggesting a potential link between female AGA and cardiovascular disease.

In this randomized clinical trial, the authors reported that adipose-derived stem cell constituent extract topical solution increased hair density and thickness in patients with androgenetic alopecia over 16 weeks compared to placebo.

In this case report, a 55-year-old woman developed alopecia areata approximately one year into her treatment with upadacitinib for atopic dermatitis, raising questions about a potential drug-induced link that has not been reported before.

This review discusses the criteria for evaluating treatments for androgenetic alopecia and emphasizes the importance of shared decision-making, noting no treatment currently meets all desired criteria of efficacy, safety, affordability, and ease of use.

This review discusses the diagnostic features of androgenetic alopecia through trichoscopy and reports no clinical results; it emphasizes hair shaft variability and yellow dots as key indicators.

This article outlines diagnosis and treatment guidelines for androgenetic alopecia but reports no new clinical findings.

This study observed that both finasteride and dutasteride significantly decreased dihydrotestosterone concentrations in hair, with dutasteride showing the greatest reduction.

This study found that patients using GLP-1 receptor agonists, specifically liraglutide, dulaglutide, and semaglutide, had a higher likelihood of being diagnosed with androgenetic alopecia, while those on exenatide showed increased odds for both androgenetic alopecia and telogen effluvium.